Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 5: Chemical in rocket fuel could be in your food. 5 On Your Side explains how dangerous it can be and how to avoid consuming it
Program
Thursday at 6 on WRAL: ð¦ Hazardous packages on your doorstep. How 1 billion packages from China bypassed safety inspectionsâand why itâs legal.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
9.930
-0.120 (-1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Travere Therapeutics Inc
< Previous
1
2
3
Next >
Travere Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties
September 29, 2023
San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc.
Via
SBWire
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
September 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
September 05, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
August 10, 2023
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 20, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
July 17, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
June 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 04, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 02, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 01, 2023
From
The Schall Law Firm
Via
Business Wire
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
May 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.